Excell Research Inc

1. Teva Pharmaceuticals USA, Inc. $1,824,088 121 payments
2. ITI, Inc. $954,069 130 payments
3. AbbVie, Inc. $889,443 192 payments
4. BioXcel Therapeutics, Inc. $705,484 10 payments
5. Boehringer Ingelheim International GmbH $385,295 78 payments
6. Biogen, Inc. $309,699 6 payments
7. Boehringer Ingelheim Pharmaceuticals, Inc. $241,755 14 payments
8. Sage Therapeutics, Inc. $228,970 5 payments
9. Janssen Research & Development, LLC $164,728 16 payments
10. Sumitomo Pharma America, Inc. $141,551 27 payments

1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $1,334,230 49 payments
2. Bxcl501401 $705,484 10 payments
3. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $288,693 24 payments
4. A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $255,988 3 payments
5. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $244,367 16 payments
6. Phase II DRF study of NR2B modulation in MDD $232,710 2 payments
7. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $216,816 2 payments
8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder $212,864 22 payments
9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia $201,164 48 payments
10. An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia $174,224 3 payments

1. Other $31,082 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.